Purpose: The outcomes of a surgical approach for patients with an esophageal carcinoma remain unsatisfactory despite its high complication rates. W e conducted a phase II trial, using com bined FP (5-fluorouracil and cisplatin) chemotherapy and concurrent radiotherapy, as a definitive therapy for patients with esophageal cancer. Results: A total of 22 eligible patients entered the study. Of the 19 evaluable patients, a complete response occurred in 7 (37% ), and a partial response in 8 (42% ). After a median follow-up of 35 months, the overall survival rate was 32% at three years and the median survival was 11 months. Fourteen (64%) received planned dose of radiotherapy and 13 (59% ) received m ore than three courses of chem otherapy. However, there was no difference in three-year survival rates between the patients that received less than three courses of chem otherapy and those that received three or more courses (31% vs. 32%). The major treatment related toxicity was mucositis, which developed in every patient, with grades III or IV in thirteen (59%) patients. During the treatm ent, the patients lost, on average, 3.8% of their body weight. The m ean hospital stay was 23 days, with a total duration of treatm ent of 74 days.
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Conclusions: Concurrent FP chem oradiotherapy was effective as a definitive therapy for patients with esophageal cancer. The m ajor toxicity was mucositis. Although the treatm ent was relatively feasible, a random ized trial of reduced courses of chem otherapy is warranted. 
